In this regard, anagliptin inhibited monocyte–macrophage differentiation and decreased tumour-associated macrophages in non-small-cell lung cancer.13 Similarly, alogliptin attenuated the recruitment and chemotaxis of monocytes via GLP-1 receptor (GLP-1R)-dependent downregulation of IL-6 and IL-1β in atherosclerotic lesions in apolipoprotein E-deficient mice.43 This evidence concerns the gene GLP1R and non-small cell lung carcinoma.